TICEBA > < Nauka

O nas

Wizja i filozofia

Nauka

Badania

Nasze Doświadczenie

Patents

W zgodzie ze standardami etycznymi

Zarządzanie i pracownicy

Zarządzanie

Nauka

Lokalizacja

Nauka

"Dorosłe komórki, ze względu na to, że mogą być pobierane łatwo i w dużych ilościach ze skóry otwierają fascynujące granice medycyny regeneracyjnej i bez wątpienia będą miały bardziej efektywne zastosowania terapeutyczne w przyszłości."
		Dr Markus Frank, asystent w Harvard Medical School jest doradcą naukowym firmy TICEBA. Obecnie zajmuje się wieloma badaniami naukowymi oraz jest wykładowcą w Harvard University w Cambridge w stanie Massachusetts w USA. Dr Frank wnosi do naszej firmy istotny wkład wiedzy na temat komórek macierzystych.

Academic Appointments • Instructor in Medicine, Harvard Medical School, Boston, MA • Principal Investigator Appointments and Responsibilities Hospital or Affiliated Institution Appointments: • Staff Physician, Department of Medicine, V.A. Medical Center, West Roxbury, • Boston, MA • Associate Physician, Renal Division, Brigham and Women's Hospital, • Boston, MA • Research Associate, Division of Nephrology, Children's Hospital, Boston, MA • Staff Physician, Department of Medicine, Faulkner Hospital, Boston, MA • Consulting Staff, Department of Medical Oncology, Dana Farber Cancer • Institute, Boston, MA • Member, Cutaneous Oncology and Melanoma Program, Dana-Farber/Harvard • Cancer Center, Boston, MA Hospital & Health Care Organization Clinical Service Responsibilities: • Attending Physician in Medicine/Emergency Medicine, V.A. Medical Center, • West Roxbury • Attending Physician in Nephrology, Brigham and Women's Hospital • Attending Physician in Nephrology, Faulkner Hospital Major Committee Assignments • Abstract Review Committee, Member, American Society of Transplantation • Abstract Review Committee, Member, American Society of Nephrology • Scientific Review Committee, Member, Israel Science Foundation • The Stem Cell Program, Member, Children's Hospital • Harvard Stem Cell Institute, Member, Harvard University • AST Cellular Transplantation Committee, Member, American Society of • Transplantation Professional Societies • American College of Physicians, Member • American Medical Association, Member • American Society of Transplantation, Member; Member Abstract Review • Committee 2002-2006, Scientific Session Co-Chair 2002-2006 • National Kidney Foundation, Member • The Transplantation Society, Member • International Society of Comparative Oncology, Member • American Society of Biochemistry and Molecular Biology, Member • American Society of Human Genetics, Member • American Society for Cell Biology, Member Editorial Boards • Ad-Hoc Reviewer, Journal of the American Society of Nephrology • Ad-Hoc Reviewer, Blood • Ad-Hoc Reviewer, Kidney International • Ad-Hoc Reviewer, Journal of Immunology • Ad-Hoc Reviewer, Molecular BioSystems (Royal Society of Chemistry, • Cambridge, UK) • Ad-Hoc Reviewer, American Journal of Physiology - Cell Physiology • Ad-Hoc Reviewer, Journal of Leukocyte Biology Bibliography Original Articles: • Frank MH, Pomer S. Interferon alpha2b differentially affects proliferation of • two human renal cell carcinoma cell lines differing in the P-glycoprotein- • associated multidrug-resistant phenotype. J Cancer Res Clin Oncol. 1999; • 125(2):117-20. • Frank MH, Denton MD, Alexander SI, Khoury SJ, Sayegh MH, Briscoe DM. • Specific MDR1 Pglycoprotein blockade inhibits human alloimmune T cell • activation in vitro. J Immunol. 2001;166 (4):2451-9. • Frank NY, Pendse SS, Lapchak PH, Margaryan A, Shlain D, Doeing C, Sayegh • MH, Frank MH. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, • a novel human ATP-binding cassette transporter. J Biol Chem. 2003; • 278(47):47156-65. • Lapchak PH, Melter M, Pal S, Flaxenburg JA, Geehan C, Frank MH, • Mukhopadhyay D, Briscoe DM. CD40-induced transcriptional activation • of vascular endothelial growth factor involves a 68- bp region of the • promoter containing a CpG island. Am J Physiol Renal Physiol. 2004; • 287(3):F512-20. • Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, • Sayegh MH, Sadee W, Frank MH. ABCB5-mediated doxorubicin transport and • chemoresistance in human malignant melanoma. Cancer Res. 2005; • 65(10):4320-33. • Lutz NW, Franks SE, Frank MH, Pomer S, Hull WE. Investigation of multidrug • resistance in cultured human renal cell carcinoma cells by 31P-NMR • spectroscopy and treatment survival assays. MAGMA. 2005;18(3):144-61. • Frank NY, Kho AT, Schatton T, Murphy GF, Molloy MJ, Zhan Q, Ramoni MF, • Frank MH, Kohane IS, Gussoni E. Regulation of myogenic progenitor • proliferation in human fetal skeletal muscle by BMP4 and its • antagonist Gremlin. J Cell Biol. 2006 Oct 9; 175(1):99-110. • Pendse SS, Behjati S, Schatton T, Izawa A, Sayegh MH, Frank MH. • P-Glycoprotein Functions as a Differentiation Switch in Antigen Presenting • Cell Maturation. Am J Transplant. 2006 Nov 3. Reviews/Chapters/Editorials: • Pendse S, Briscoe DM, Frank MH. P-glycoprotein and alloimmune T cell • activation. Clinical and Applied Immunology Reviews. 2003;4(1):3-14. • Pendse S, Sayegh MH, Frank MH. P-glycoprotein - a novel therapeutic target • for immunomodulation in clinical transplantation and autoimmunity? Curr Drug • Targets. 2003;4(6):469-76. • Frank MH, Sayegh MH. Immunomodulatory functions of mesenchymal stem • cells. Lancet. 2004;363(9419):1411-2. Books, Monographs, and Textbooks: • Frank MH, Sayegh MH. Transplantation Tolerance. In: Transplantation 1999: • Progress on the Cusp of the Millennium. New York (NY): Lippincott Williams & • Wilkins Healthcare;1999. • Frank MH, Sayegh MH. Immunology and Tolerance. In: Transplantation 2000: • Transplantation at the Millennium. New York (NY): Lippincott Williams & Wilkins • Healthcare;2000. • Frank MH, Sayegh MH. Tolerance: is it time to move to the clinic? In: Current • and Future Immunosuppressive Therapies Following Transplantation. • Dordrecht, The Netherlands: Kluwer Academic Publishers;2001. p. 293-313. • (Mohamed Sayegh and Giuseppe Remuzzi, editors.) • Frank MH, Sayegh MH. Immunology and Tolerance. In: Transplantation 2001. • New York (NY): Lippincott Williams & Wilkins Healthcare;2001. • Frank MH. Briscoe DM. Monoclonal Antibody Targeting of Adhesion Molecules. • In: Current and Future Immunosuppressive Therapies Following • Transplantation. Dordrecht, The Netherlands: Kluwer Academic Publishers; • 2001. p. 249-263. (Mohamed Sayegh and Giuseppe Remuzzi, editors.) Abstracts: • Frank MH, Shedd SF, Lutz NW, Pomer S, Hull WE. 31P Nuclear Magnetic • Resonance Spectroscopy Study of Multidrug Resistance in Human Renal Cell • Carcinoma. Society of Magnetic Resonance in Medicine 12th Annual • Conference New York, NY. 1993:1015. • Shedd SF, Lutz NW, Frank MH, Hull WE. Choline- and Ethanolamine- • Dependent Regulation of Phosphomonoester and Uridine diphospho-hexose • Metabolism in a Human Colon Cancer Cell Line. Society of Magnetic • Resonance in Medicine 12th Annual Conference New York, NY. 1993:262. • Lu R, Frank M, Schuster VL. Genomic Cloning of the Human Prostaglandin • (PG) Transporter "PGT" Gene. Journal of the American Society of Nephrology. • 1996;7:A1997. • Frank MH, Pomer S. IFN-alpha differentially affects proliferation of two renal • cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug • resistance phenotype. UICC 17th International Cancer Congress August 23-28 • 1998, Rio de Janeiro - Brazil. 1998:A1143. • Frank MH, Denton MD, Alexander SI, Khoury SJ, Sayegh MH, Briscoe DM. • P-glycoprotein is functional in antigen- and alloantigen-dependent T cell • activation. Journal of the American Society of Nephrology. 1999;10:A3551. • Denton MD, Frank MH, Waaga AM, Geehan C, Sayegh MH, Briscoe DM. Human • endothelial cells facilitate indirect allorecognition. Journal of the American • Society of Nephrology. 1999;10:A3540. • Frank MH, Denton MD, Khoury SJ, Briscoe DM, Sayegh MH. Modulators of • P-glycoproteinmediated transmembrane transport inhibit T-cell proliferation • in vitro. Transplantation. 1999;67 (S63):A225. • Frank MH, Denton MD, Alexander SI, Khoury SJ, Sayegh MH, Briscoe DM. • P-glycoprotein blockade inhibits alloimmune T cell activation in vitro. XVIII • International Congress of the Transplantation Society, Rome, Italy, 2000. • 2000:p161: Abstract POO26W. • Frank MH, Chitnis T, Abdallah KA, Sayegh MH, Khoury SJ. Tamoxifen inhibits • disease expression in murine experimental autoimmune encephalomyelitis. • Neurology. 2000;54(7 Suppl 3):A61. • Frank MH, Sayegh MH, Briscoe DM. P-glycoprotein function in human • alloimmune interactions. Pediatric Transplantation. 2000;4 (Supplement • No. 2):108: Abstract 0178. • Frank MH, Sayegh MH, Briscoe DM. P-glycoprotein function in alloimmune • lymphocyte/endothelial cell interactions. Journal of the American Society • of Nephrology. 2000;11:661A: A3485. • Frank MH, Sayegh MH, Briscoe DM. P-glycoprotein function in human • alloimmune interactions. Transplantation. 2000;69(8):A78. • Frank MH, Sayegh MH, Briscoe DM. P-glycoprotein blockade inhibits • alloimmune T cell responses via both CD4+ T cell- and CD14+ • APC-dependent activation pathways. American Journal of Transplantation. • 2001;1(Supplement 1):267: Abstract# 527. • Pendse S, Sayegh, MH, Frank MH. A critical role for P-glycoprotein in early • cytokine-dependent dendritic cell maturation. American Journal of • Transplantation 2002. 2002;2(Supplement 3):265: Abstract# 504. • Pendse S, Sayegh, MH, Frank MH. MDR1 P-glycoprotein blockade inhibits early • cytokinedependent dendritic cell differentiation. Journal of the American • Society of Nephrology. 2002;13:53A. • Izawa A, Frank NY, Pendse S, Sayegh MH, Frank MH. P-glycoprotein blockade • prolongs murine cardiac allograft survival. Circulation. 2003;108(17):IV-331 • Abstract 1554. • Frank NY, Pendse S, Lapchak PH, Doeing C, Sayegh MH, Frank MH. Regulation • of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding • cassette transporter. American Journal of Human Genetics. 2003;73 • (5 Supplement):327 Abstract 921. • Izawa A, Pendse S, Sayegh MH, Frank MH. MDR1 Specific pharmacologic • P-glycoprotein blockade prolongs murine cardiac allograft survival. American • Journal of Transplantation. 2003;3(Supplement 5):447: Abstract# 1153. • Pendse S, Behjati S, Sayegh MH, Frank MH. MDR1 P-glycoprotein is a dendritic • cell/macrophage differentiation switch in antigen presenting cell maturation. • American Journal of Transplantation. 2003;3(Supplement 5):340: • Abstract# 732. • Frank N, Frank MH, Gussoni E. ABCB5 P-glycoprotein is a molecular marker of • the Hoechst 33342 side population phenotype among human fetal skeletal • muscle cells. The FASEB Journal. 2004;18(4):A183: Abstract 144.9. • Margaryan A, Pütz P, Sayegh MH, Frank MH. Skin-derived ABCB5+ • progenitors can be induced to generate insulin-secreting cells in vitro. • The Cell Transplant Society 7th International Congress, Boston, USA, • November 17-20, 2004. 2004;18:Abstract 124. • Margaryan A, Sayegh MH, Frank MH. In vitro generation of insulin-secreting • cells from adult skin-derived ABCB5+ progenitors. Journal of the American • Society of Nephrology. 2004;15:647A. • Izawa A, Frank NY, Pendse SS, Margaryan A, Sho M, Sayegh MH, Frank MH. • In vivo regulation of Th1 responses and murine cardiac allograft rejection by • multidrug resistance Pglycoprotein. American Journal of Transplantation. • 2004;4(Supplement 8):412: Abstract# 931. • Frank NY, Margaryan A, Huang Y, Waaga-Gasser AM, Gasser M, Sayegh MH, • Sadee W, Frank MH. ABCB5-mediated doxorubicin transport and • chemoresistance in human malignant melanoma. Proceedings of the American • Association for Cancer Research. 2005;46:554 Abstract #2362. • Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, • Sayegh MH, Sadee W, Frank MH. ABCB5-mediated chemoresistance in human • malignant melanoma. 13th SPORE Investigators' Workshop,Washington, DC, • July 9-12, 2005. 2005:150 Abstract #149. • Rigol N, Frank NY, Margaryan A, Schatton T, Frank MH. Differential expression • of ABCB5 multidrug resistance P-glycoprotein in human breast cancer cell • lines. Proceedings of the Department of Defense Breast Cancer Research • Program Meeting (Era of Hope), June 8-11, 2005, Philadelphia, PA. 2005:467 • Abstract P66-7. • Schatton T, Yamaura K, Kupper TS, Sayegh MH, Murphy GF, Frank MH. • ABCB5: A Novel Molecular Marker For Melanoma Stem Cells? The Tony • & Shelly Malkin Stem Cell Symposium, Harvard Stem Cell Institute, • Boston, MA. 2005. • Schatton T, Murphy GF, Frank NY, Yamaura K, Zhan Q, Rigol N, Margaryan A, • Jordan S, Duncan LM, Kupper TS, Sayegh MH, Frank MH. The chemoresistance • mediator ABCB5 identifies melanoma stem cells. National Cancer Institute • 14th SPORE Investigators' Workshop. 2006:Abstract 150, p. 92. • Schatten S, Yang J, Chandraker A, Sayegh MH, Frank MH. In vivo • immunomodulatory function of ABCB5+ dermal mesenchymal stem cells. • American Journal of Transplantation. 2006;Supplement(World Transplant • Congress):Abstract 351: pp. 185-186.